Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage

Cell Cycle

Volumn 11, Issue 8, 2012, Pages 1573-1582

  Moudry, Pavel ^a,b   Lukas, Claudia ^b   Macurek, Libor ^a   Hanzlikova, Hana ^a   Hodny, Zdenek ^a   Lukas, Jiri ^b   Bartek, Jiri ^a,b,c  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

53BP1; DNA damage response; UBA1; UBA6; Ubiquitin activating enzyme; Ubiquitylation

Indexed keywords

BRCA1 PROTEIN; PROTEIN UBA1; PROTEIN UBA6; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; UBIQUITINATION;

ATAXIA TELANGIECTASIA;

EID: 84860338316     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19978     Document Type: Article

References (39)

1. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/ nature08467.
2. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat Cell Biol 2011; 13:1161-9; PMID:21968989; http://dx.doi.org/10.1038/ncb2344.
3. Xu Y, Price BD. Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle 2011; 10:261-7; PMID:21212734; http://dx.doi.org/10.4161/cc. 10.2.14543.
4. Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D, et al. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 2003; 421:952-6; PMID:12607003; http://dx.doi.org/10.1038/nature01445.
5. Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007; 318:1637-40; PMID:18006705; http:// dx.doi.org/10.1126/science.1150034.
6. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007; 131:887-900; PMID:18001824; http://dx.doi.org/10.1016/j.cell.2007.09.040.
7. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R, et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 2009; 136:435-46; PMID:19203579; http://dx.doi.org/10.1016/j.cell.2008.12.041.
8. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 2009; 136:420-34; PMID:19203578; http://dx.doi.org/10.1016/j.cell.2008.12.042.
9. Mallette FA, Mattiroli F, Cui G, Young LC, Hendzel MJ, Mer G, et al. RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 2012; In press; PMID:22373579; http://dx.doi.org/10.1038/emboj.2012.47.
10. Al-Hakim A, Escribano-Diaz C, Landry MC, O'Donnell L, Panier S, Szilard RK, et al. The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst) 2010; 9:1229-40; PMID:21056014; http://dx.doi.org/10.1016/j. dnarep.2010.09.011.
11. Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL. Molecular cloning, sequence and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Natl Acad Sci USA 1991; 88:258-62; PMID:1986373; http://dx.doi.org/10.1073/pnas.88.1.258.
12. Chiu YH, Sun Q, Chen ZJ. E1-L2 activates both ubiquitin and FAT10. Mol Cell 2007; 27:1014-23; PMID:17889673; http://dx.doi.org/10.1016/j.molcel.2007. 08.020.
13. Jin J, Li X, Gygi SP, Harper JW. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 2007; 447:1135-8; PMID:17597759; http://dx.doi.org/10.1038/nature05902.
14. Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M, et al. UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 2007; 282:23010-4; PMID:17580310; http://dx.doi.org/10.1074/jbc.C700111200.
15. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009; 10:319-31; PMID:19352404; http://dx.doi.org/10.1038/ nrm2673.
16. Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010; 9:389-97; PMID:20046100; http://dx.doi.org/10.4161/cc. 9.2.10475.
17. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 2003; 5:255-60; PMID:12598907; http://dx.doi.org/10.1038/ncb945.
18. Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Pedersen RS, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol 2011; 13:243-53; PMID:21317883; http://dx.doi.org/10.1038/ncb2201.
19. Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007; 67:9472-81; PMID:17909057; http://dx.doi.org/10. 1158/0008-5472.CAN-07-0568.
20. Harrigan JA, Belotserkovskaya R, Coates J, Dimitrova DS, Polo SE, Bradshaw CR, et al. Replication stress induces 53BP1-containing OPT domains in G1 cells. J Cell Biol 2011; 193:97-108; PMID:21444690; http:// dx.doi.org/10.1083/jcb.201011083.
21. Lee PC, Sowa ME, Gygi SP, Harper JW. Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. Mol Cell 2011; 43:392-405; PMID:21816346; http://dx.doi.org/10.1016/j.molcel.2011.05.034.
22. Moudry P, Lukas C, Macurek L, Neumann B, Heriche JK, Pepperkok R, et al. Nucleoporin NUP153 guards genome integrity by promoting nuclear import of 53BP1. Cell Death Differ 2011; In press; PMID:22075984; http://dx.doi.org/10.1038/cdd. 2011.150.
23. Palle K, Vaziri C. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition. Cell Cycle 2011; 10:1625-38; PMID:21478670; http://dx.doi.org/10. 4161/cc.10.10.15617.
24. Devgan SS, Sanal O, Doil C, Nakamura K, Nahas SA, Pettijohn K, et al. Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia. Cell Death Differ 2011; 18:1500-6; PMID:21394101; http://dx.doi.org/10.1038/cdd.2011.18.
25. Stewart GS, Stankovic T, Byrd PJ, Wechsler T, Miller ES, Huissoon A, et al. RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci USA 2007; 104:16910-5; PMID:17940005; http://dx.doi.org/10.1073/pnas.0708408104.
26. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007; 6:2344-7; PMID:17700066; http://dx.doi.org/10.4161/cc.6.19. 4754.
27. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70; PMID:15829956; http:// dx.doi.org/10.1038/nature03482.
28. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; PMID:15829965; http://dx.doi.org/10.1038/nature03485.
29. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene- induced DNA damage model for cancer development. Science 2008; 319:1352-5; PMID:18323444; http://dx.doi.org/10.1126/science.1140735.
30. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6; PMID:17525332; http://dx.doi.org/10.1126/science.1140321.
31. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145:30-8; PMID:21458666; http://dx.doi.org/10.1016/j.cell.2011.03.020.
32. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10:1192-9; PMID:21487248; http://dx.doi.org/10.4161/ cc.10.8.15273.
33. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10:2121-8; PMID:21610326; http://dx.doi.org/10.4161/cc.10.13.16398.
34. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 2011; 10:4321-9; PMID:22134241; http://dx.doi.org/10.4161/cc.10.24.18661.
35. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319:620-4; PMID:18239126; http://dx.doi.org/10.1126/science.1149200.
36. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011; 11:239-53; PMID:21247388; http://dx.doi.org/10. 2174/156800911794519752.
37. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010; 115:2251-9; PMID:20075161; http://dx.doi.org/10.1182/blood-2009-07-231191.
38. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle 2011; 10:457-68; PMID:21248468; http://dx.doi.org/10.4161/cc.10.3.14707.
39. Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, et al. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle 2010; 9:3085-99; PMID:20699642; http://dx.doi.org/10.4161/cc.9.15.12521.